These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 37992600)
1. Inhaled pulmonary surfactant biomimetic liposomes for reversing idiopathic pulmonary fibrosis through synergistic therapeutic strategy. Wang B; Gao Y; Sun L; Xue M; Wang M; Zhang Z; Zhang L; Zhang H Biomaterials; 2023 Dec; 303():122404. PubMed ID: 37992600 [TBL] [Abstract][Full Text] [Related]
2. Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Kurita Y; Araya J; Minagawa S; Hara H; Ichikawa A; Saito N; Kadota T; Tsubouchi K; Sato N; Yoshida M; Kobayashi K; Ito S; Fujita Y; Utsumi H; Yanagisawa H; Hashimoto M; Wakui H; Yoshii Y; Ishikawa T; Numata T; Kaneko Y; Asano H; Yamashita M; Odaka M; Morikawa T; Nakayama K; Kuwano K Respir Res; 2017 Jun; 18(1):114. PubMed ID: 28577568 [TBL] [Abstract][Full Text] [Related]
3. ROS-responsive liposomes as an inhaled drug delivery nanoplatform for idiopathic pulmonary fibrosis treatment via Nrf2 signaling. Liu J; Wu Z; Liu Y; Zhan Z; Yang L; Wang C; Jiang Q; Ran H; Li P; Wang Z J Nanobiotechnology; 2022 May; 20(1):213. PubMed ID: 35524280 [TBL] [Abstract][Full Text] [Related]
4. Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapy. Yang MY; Lin YJ; Han MM; Bi YY; He XY; Xing L; Jeong JH; Zhou TJ; Jiang HL J Control Release; 2022 Nov; 351():623-637. PubMed ID: 36191673 [TBL] [Abstract][Full Text] [Related]
5. Traditional Chinese medicine inspired dual-drugs loaded inhalable nano-therapeutics alleviated idiopathic pulmonary fibrosis by targeting early inflammation and late fibrosis. Zheng M; Liu K; Li L; Feng C; Wu G J Nanobiotechnology; 2024 Jan; 22(1):14. PubMed ID: 38166847 [TBL] [Abstract][Full Text] [Related]
6. A fibroblastic foci-targeting and hypoxia-cleavable delivery system of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Zhao T; Gong B; Luo S; Zhang R; Zhang L; Huang Y; Gao H; Gong T Acta Biomater; 2023 Sep; 167():574-582. PubMed ID: 37356783 [TBL] [Abstract][Full Text] [Related]
7. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation. Vu TN; Chen X; Foda HD; Smaldone GC; Hasaneen NA Respir Res; 2019 Sep; 20(1):206. PubMed ID: 31511015 [TBL] [Abstract][Full Text] [Related]
8. Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI. Sun N; Fernandez IE; Wei M; Witting M; Aichler M; Feuchtinger A; Burgstaller G; Verleden SE; Schmitt-Kopplin P; Eickelberg O; Walch A Eur Respir J; 2018 Sep; 52(3):. PubMed ID: 30072508 [TBL] [Abstract][Full Text] [Related]
9. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. Liu Y; Lu F; Kang L; Wang Z; Wang Y BMC Pulm Med; 2017 Apr; 17(1):63. PubMed ID: 28420366 [TBL] [Abstract][Full Text] [Related]
10. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib. Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895 [TBL] [Abstract][Full Text] [Related]
11. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients. Feng H; Zhao Y; Li Z; Kang J Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis. Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058 [TBL] [Abstract][Full Text] [Related]
13. The Role of Pulmonary Surfactant Phospholipids in Fibrotic Lung Diseases. Tlatelpa-Romero B; Cázares-Ordoñez V; Oyarzábal LF; Vázquez-de-Lara LG Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613771 [TBL] [Abstract][Full Text] [Related]
14. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. Xie Y; Jiang H; Zhang Q; Mehrotra S; Abel PW; Toews ML; Wolff DW; Rennard S; Panettieri RA; Casale TB; Tu Y Respir Res; 2016 Aug; 17(1):103. PubMed ID: 27549302 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluation of pirfenidone-NSAIDs conjugates for the treatment of idiopathic pulmonary fibrosis. Lu X; Zhu C; Gao Y; Yu Z; Yan Q; Liu Y; Luo M; Shi X Bioorg Chem; 2024 Feb; 143():107018. PubMed ID: 38071874 [TBL] [Abstract][Full Text] [Related]
17. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219 [TBL] [Abstract][Full Text] [Related]
18. Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for idiopathic pulmonary fibrosis. Togami K; Kanehira Y; Tada H Biol Pharm Bull; 2013; 36(10):1525-7. PubMed ID: 24088250 [TBL] [Abstract][Full Text] [Related]
19. Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go? Singh V; Ulasov I; Gupta S; Singh A; Roy VK; Kharwar RK Discov Med; 2024 Jan; 36(180):22-47. PubMed ID: 38273744 [TBL] [Abstract][Full Text] [Related]
20. Stability and Activity of Interferon Beta to Treat Idiopathic Pulmonary Fibrosis with Different Nebulizer Technologies. Brun EHC; Hong ZY; Hsu YM; Wang CT; Chung DJ; Ng SK; Lee YH; Wei TT J Aerosol Med Pulm Drug Deliv; 2023 Apr; 36(2):55-64. PubMed ID: 36827329 [No Abstract] [Full Text] [Related] [Next] [New Search]